New therapeutic treatment approach improves survival in esophageal cancer patients

Oct 06, 2008

A study released at the 73rd Annual Scientific Meeting of the American College of Gastroenterology in Orlando found that a new therapeutic treatment, when delivered endoscopically and used in combination with chemotherapy and radiation therapy, improved survival rates in patients with locally advanced esophageal cancer. Cancer of the esophagus often has a poor survival rate.

Dr. Kenneth Chang of University of California Irvine Medical Center and his colleagues conducted a Phase 2 multi-center study on the safety and long-term efficacy of a new biologic therapy (TNFeradeTM), an injection of an anti-tumor agent, in 24 patients with locally advanced esophageal cancer.

Patients received standard care chemotherapy and radiation. In addition, the patients received TNFeradeTM through a standard endoscope or endoscopic ultrasound that guided the injection directly into the esophageal tumor. TNFeradeTM contains a non-replicating virus, which has been engineered to deliver the gene for a cancer fighting protein, TNF-alpha and works synergistically with chemoradiation representing a "triple threat" to cancer cells.

TNFeradeTM was administered once a week for a total of 5 treatments. Surgery was performed 5-11 weeks after completion of therapy. Researchers monitored the effects of this combined therapy by observing the side effects, tumor response, and overall survival.

Researchers found most tumors were of the "adenocarcinoma" type. These tumors were locally advanced (had gone through the deeper layers of the esophagus and/or had spread to lymph nodes) but still potential candidates for surgery.

TNFeradeTM in combination with chemoradiation in this group of patients, resulted in a median survival of 48.4 months, in contrast to previously published trials showing a median survival of 9.7 to 34 months. At one particular dose all four of the patients were alive without any recurrence at 48 months. Three of these patients had tumor resections, which showed no residual cancer cells in the surgical specimens.

According to lead investigator Dr. Chang, "This new treatment, in combination with chemoradiation in this group of patients, represents an encouraging increase in survival relative to historical controls and therefore warrants additional evaluation. TNFeradeTM is a promising treatment that represents a new paradigm in esophageal cancer treatment, with the gastroenterologist administering the local anti-tumor agent through a scope."

Source: American College of Gastroenterology

Explore further: Researchers uncover powerful new class of weapons in the war on cancer

add to favorites email to friend print save as pdf

Related Stories

Feds: Don't expect winter to be polar vortex redux

21 minutes ago

(AP)—Federal forecasters don't expect a return of frequent cold blasts from the polar vortex this winter. Nor should the weather system that blocked rain from California last winter come back.

WASP has printer, will travel, to make houses

25 minutes ago

At Maker Faire Rome, an Italian 3D printer company is demonstrating a tall, portable machine that will bring 3D-printed dwellings to impoverished countries. WASP has been exploring low-cost solutions to ...

Cadavers beat computers for learning anatomy

5 minutes ago

Despite the growing popularity of using computer simulation to help teach college anatomy, students learn much better through the traditional use of human cadavers, according to new research that has implications ...

Cell architecture: Finding common ground

28 minutes ago

When it comes to cellular architecture, function follows form. Plant cells contain a dynamic cytoskeleton which is responsible for directing cell growth, development, movement, and division. So over time, changes in the cytoskeleton ...

Recommended for you

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

E_L_Earnhardt
not rated yet Oct 07, 2008
Suspect it was the "endoscope" that did it, Conducting away excess electrons!